What is the clinical evidence from this study?

Study design: Review. Population: Type 2 Diabetes Mellitus and Chronic Kidney Disease. Intervention: Combination pharmacotherapy (SGLT2 inhibitors, nsMRAs, GLP-1 RAs, and RAAS blockade).

What question did this study set out to answer?

To review the clinical evidence and mechanistic rationale supporting multi-target combination pharmacotherapies for patients with comorbid type 2 diabetes mellitus and chronic kidney disease.

August 20, 2026

Combination Pharmacotherapy in Type 2 Diabetes and Chronic Kidney Disease: Translating Evidence into Clinical Practice.

View Full Paper

Ask AI

Bookmark

Key result

Combination pharmacotherapy improves survival and cuts cardiovascular events and ESKD progression in T2DM and CKD.

Why the study?

CKD in T2DM poses high renal and cardiovascular risks, and advances in pharmacotherapies support simultaneous combinatory therapies targeting distinct mechanistic pathways.

Population

Patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD)

Design

Review

Authors

JLJulie A. LovshinSunnybrook Health Science Centre

Discussion

Member takes

Implication

May support multi-pathway combinations in T2DM-CKD; leaves open need for RCTs before practice change.

Key Points

To review the clinical evidence and mechanistic rationale supporting multi-target combination pharmacotherapies for patients with comorbid type 2 diabetes mellitus and chronic kidney disease.
Reviewed 25 years of therapeutic developments and clinical trial evidence in type 2 diabetes mellitus and chronic kidney disease.
Evaluated the distinct mechanisms and cumulative benefits of SGLT2 inhibitors, nsMRAs, GLP-1 RAs, and RAAS inhibitors (ACE inhibitors or ARBs).
Chronic kidney disease develops in approximately 30% to 40% of patients with type 2 diabetes mellitus, significantly elevating risk for end-stage renal disease, cardiovascular events, and premature mortality.
Simultaneous combination pharmacotherapy targeting complementary pathophysiological pathways demonstrates parallel reductions in renal and cardiovascular risk, resulting in improved survival and reduced dialysis initiation.

Structured PICO

Population

Patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD)

Intervention

Combination pharmacotherapy including sodium-glucose cotransporter 2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (nsMRAs), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and renin angiotensin aldosterone system (RAAS) blockade with ACEi or ARBs

Recent evidence supports the simultaneous use of combination pharmacotherapies targeting distinct pathophysiological pathways to reduce renal and cardiovascular risk in patients with T2DM and CKD.

Cite This Study

Julie A. Lovshin (2026) conducted a review in Type 2 Diabetes Mellitus and Chronic Kidney Disease. Combination pharmacotherapy (SGLT2 inhibitors, nsMRAs, GLP-1 RAs, and RAAS blockade) was evaluated. Combination pharmacotherapy targeting distinct mechanistic pathways improves survival and reduces cardiovascular events and progression to end-stage renal failure in patients with T2DM and CKD.

synapsesocial.com/papers/6a86b5ff8a91293e6a1cda61 https://doi.org/10.1093/ndt/gfag136

View Full Paper

Ask AI

Bookmark

Combination Pharmacotherapy in Type 2 Diabetes and Chronic Kidney Disease: Translating Evidence into Clinical Practice.

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Combination Pharmacotherapy in Type 2 Diabetes and Chronic Kidney Disease: Translating Evidence into Clinical Practice.

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider